Interview with Lee Rodne, CEO of Admedus
Admedus has had an interesting couple of months including the completion of a successful capital raising. The company has three business divisions, however, in this interview we focus specifically on the tissue regenerative medicines business. The lead product in this business is called Cardiocell and we ask Lee to share some more insights into this part of the Admedus business.
1 stock mentioned
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
No areas of expertise